March 21, 2026, Beijing, China — Grand Life Sciences Group Co., Ltd. (hereinafter referred to as "Grand Life Sciences") and Belief BioMed Inc. (hereinafter referred to as "Belief BioMed") officially signed an exclusive commercialization cooperation agreement in Beijing. Under the agreement, Grand Life Sciences secured exclusive commercialization rights in the Chinese mainland, Hong Kong, Macau, and Taiwan regions of China for Belief BioMed's investigational product BBM-H803 Injection, a gene the

Recently, the Health Commission of Sichuan Province officially released the list of provincial healthy enterprises. Grand Shuyang was honored with the title of “Provincial Healthy Enterprise of Sichuan.” for its outstanding practices in the field of health management. This honor signifies that the Company's overall capabilities in corporate health promotion have been acknowledged by provincial authorities.

Recently, Grand Shuyang was officially certified as a "Healthy Enterprise" in Chengdu, marking a significant achievement in employee health management, corporate humanistic development, and sustainable development. The Company has currently initiated the application process for provincial-level Healthy Enterprise certification and continues to advance its health management to a higher standard.

December 12, 2025, Chengdu—To fully implement the "Healthy China" initiative, further promote the spirit of humanitarian dedication, and advance the standardization and sustainable development of source plasma management in the blood products industry, Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as "Grand Shuyang") held the "2025 Annual Commendation for Plasma Donors and Blood Source Development Conference".

The "2nd China Plasma Protein Industry Development Conference" was held in Chengdu, Sichuan from November 07 to 09, 2025. Themed "Plasma Protein Drugs: Enhancing Independent Innovation Capabilities and Upgrading Industrial Development Level", this conference was hosted by the China Biochemical Pharmaceutical Industry Association and organized by the Institute of Blood Transfusion of the Chinese Academy of Medical Sciences and the Plasma Protein Branch of the Association. It brought together indu

On November 14–16, 2025, the "2025 Animal-related Injury Prevention and Treatment Conference", hosted by the Animal Injury Treatment Branch of the China Association for Disaster & Emergency Rescue Medicine, was successfully held in Wuhan City, Hubei Province. As a benchmark enterprise in the Chinese blood products industry, a long-standing practitioner in rabies prevention and control, and a strategic partner of the conference, Grand Shuyang has actively engaged in academic exchanges for years, 

Recently, the 26th CPHI Worldwide — a premier annual event for the global pharmaceutical industry — was successfully held at Messe Frankfurt in Germany. As a top international platform covering the entire pharmaceutical value chain, this convention attracted nearly 2000 exhibitors and more than 60,000 professional visitors from over 160 countries and regions to explore innovation trends and cooperation opportunities in the global biopharmaceutical industry.

Recently, the Tumed Right Banner in Baotou City, Inner Mongolia Autonomous Region, experienced unprecedented heavy rainfall, leading to severe flooding. Houses in Shuanglong Town and surrounding areas were flooded, roads were cut off, significantly impacting the daily lives of many residents, and the disaster-stricken areas urgently required supplies.

Recently, the Administration for Market Regulation of Sichuan Province (Intellectual Property Administration) officially announced the List of Leading Intellectual Property Enterprises in Sichuan Province for 2025. After several rounds of rigorous evaluation, Grand Shuyang was successfully included in the list due to its outstanding comprehensive strength in IPR creation, application, management, and protection, becoming one of the 14 enterprises in Chengdu to receive this recognition.

Recently, the production line for the fourth-generation human immunoglobulin for intravenous injection of Grand Shuyang Life Sciences (Chengdu) Co., Ltd. was officially commissioned. The project is designed according to EU GMP standards, with an annual plasma feeding capacity of 3000 tons, positioning it as a leading large-scale production line with advanced technology for the human immunoglobulin for intravenous injection.

Recently, Professor Chen Fangruo, Dean of Antai College of Economics & Management, Dean of Institute of Industry Research, and Dean of Shenzhen Research Institute of Shanghai Jiao Tong University, led a delegation of over 20 professors to visit Grand Shuyang Life Sciences (Chengdu) Co., Ltd. for research and academic exchange.

Recently, 25% human albumin independently developed by Grand Shuyang, a subsidiary of Grand Life Sciences Group Co., Ltd., was officially approved for marketing by the National Medical Products Administration (NMPA). The marketing of this product fills the supply gap for high-concentration human albumin in the Chinese market and provides more efficient and precise treatment protocols for critically ill patients in clinical settings.